Tomorrow at #ESMO26: MSK hepatopancreatobiliary surgeon Dr. Vinod Balachandran (@TheVinodLab) will discuss immunotherapy in pancreatic cancer and overcoming barriers to success. 🗓️ Monday, October 26 | 11:15 a.m. CET

Tomorrow at #ESMO26: MSK sarcoma medical oncologist Dr. Lauren Banks will present research on lifileucel in undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma. 🗓️ Monday, October 26 | 9:34 a.m. CET

Today at #ESMO26: Research co-authored by MSK gastrointestinal medical oncologist Dr. Yelena Janjigian will be presented from CLARITY-Gastric 01, a phase 3 study of sonesitatug vedotin in second- or later-line advanced or metastatic Claudin 18.2-positive gastroesophageal carcinoma. 🗓️ Sunday, October 25 | 5:18 p.m. CET

Coming up at #ESMO26: MSK thoracic surgeon Dr. Daniela Molena will discuss perioperative therapy for locally advanced gastric and gastroesophageal cancer. 🗓️ Sunday, October 25 | 4:30 p.m. CET

Tomorrow at #ESMO26: MSK gastrointestinal medical oncologist @AndreaCercek will present the first results from the global AZUR1 trial of dostarlimab monotherapy in patients with dMMR/MSI-H locally advanced rectal cancer. 🗓️ Sunday, October 25 | 11:00 a.m. CET

Coming up at #ESMO26: MSK cancer biologist @nikolausschultz will present on AI-augmented integration of real-world data to improve cancer outcome prediction. 🗓️ Saturday, October 24 | 12:20 p.m. CEST

Tomorrow at #ESMO26: MSK melanoma medical oncologist Dr. Michael Postow will present a poster on real-world outcomes among patients with resectable stage III melanoma treated with neoadjuvant nivolumab plus relatlimab or nivolumab plus ipilimumab. 🗓️ Saturday, October 24 | 12:00 p.m. CEST

Good news for #melanoma cancer patients: New results from a personalized #cancervaccine designed to prevent melanoma from returning after surgery showed positive results, according to research presented at this year’s #ESMO26 meeting in Madrid. The study found that adding a specially tailored cancer vaccine to standard treatment with immunotherapy successfully reduced the risk of melanoma coming back by 42% compared with standard immunotherapy alone. “The idea of this treatment is that by specifically boosting a patient’s immune system to recognize their own tumor cells, we can reduce the risk that the cancer comes back,” says Dr. Michael Postow, Chief of the Melanoma Service at MSK. “Even when we can’t see any cancer on a CT or PET scan, we know that often it’s still there — because such a high proportion of patients eventually have a cancer recurrence. That’s why there is tremendous need for this type of treatment.” Read more about one of the three MSK patients treated in the trial: bit.ly/3W0Voj2

A new vaccine continues to show potential as a ready-made treatment for pancreatic cancer, according to a study co-led by MSK researchers. MSK's @EileenMOReilly presented phase 2 results from AMPLIFY-7P at #ESMO26. The vaccine targets KRAS mutations, which are found in more than 90% of pancreatic cancers. 99% of patients receiving the vaccine developed cancer-fighting immune T cells. Patients with the strongest immune responses had the lowest recurrence rates. “Having a vaccine that’s ‘off-the-shelf’ would make it easier, faster, and less expensive to treat a larger number of patients,” says Dr. O’Reilly. “This gives hope for people with pancreatic cancer who have been out of effective treatments when their disease returns.” Learn more: bit.ly/3VSsO3h

Coming up at #ESMO26: MSK gastrointestinal medical oncologist @EileenMOReilly will present the AMPLIFY-7P randomized phase 2 study comparing an mKRAS-specific immunotherapy with observation in patients with resected pancreatic ductal adenocarcinoma. 🗓️ Friday, October 23 | 2:32 p.m. CEST

Through a recent collaboration, Memorial Sloan Kettering Cancer Center (MSK) and @OpenEvidence are making precision oncology expertise more accessible within clinicians’ everyday workflows. The collaboration brings OpenEvidence and MSK's OncoKB™ knowledge base together to help deliver trusted, evidence-based guidance when and where it’s needed most. Watch to learn more ⬇️